Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Chen, Wei Prof. Dr. (1) Daniel, Peter Prof. Dr. (2) Janz, Martin Dr. (10) Kammertöns, Thomas Dr. (5) Kirchner, Marieluise Dr. (1) Kopp, Joachim Dr. (1) Landthaler, Markus Prof. Dr. (1) Leisegang, Matthias Prof. Dr. rer. nat. (2) Mathas, Stephan Dr. (10) Nguyen, Tam Hoai Dr. (1) Pezzutto, Antonio Prof. Dr. (2) Rajewsky, Nikolaus Prof. Dr. (1) Selbach, Matthias Prof. Dr. (11) Uckert, Wolfgang Prof. Dr. (4) Willimsky, Gerald Dr. (1) Wolf, Jana Prof. Dr. (1) Wollert-Wulf, Brigitte (2) (-) Blankenstein, Thomas Prof. Dr. (14) (-) Lusatis, Simone (1) (-) Biologie maligner Lymphome (1) Genetik und Genomik von Herz- Kreislauferkrankungen (1) (-) Molekulare Immunologie und Gentherapie (14) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) (-) 2004 (8) 2005 (10) (-) 2006 (2) 2007 (5) 2008 (5) 2009 (2) 2010 (7) (-) 2011 (5) 2012 (6) 2013 (11) 2014 (4) 2015 (3) 2016 (4) 2017 (6) 2018 (4) 2019 (6) 2021 (4) 2022 (6) 2023 (5) 2024 (2) 15 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Lusatis, SimoneBiologie maligner LymphomeMolekulare Immunologie und Gentherapie 200420062011 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert 01. Januar 2004 / J Immunol Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells H.J. Kim T. Kammertoens M. Janke O. Schmetzer Z. Qin C. Berek T. Blankenstein 01. Januar 2004 / Gene Ther Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization J. Westermann T. Nguyen-Hoai A. Mollweide G. Richter O. Schmetzer H.J. Kim T. Blankenstein B. Doerken A. Pezzutto 01. August 2004 / Immunity CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions L. Ohl M. Mohaupt N. Czeloth G. Hintzen Z. Kiafard J. Zwirner T. Blankenstein G. Henning R. Foerster 01. Juli 2004 / Eur J Immunol Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors M. Gladow W. Uckert T. Blankenstein 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 01. Januar 2004 / Nat Immunol A cancer immunosurveillance controversy Z.H. Qin T. Blankenstein 01. Januar 2004 / Int J Cancer CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells J.A. Lindencrona S. Preiss T. Kammertoens T. Schueler M. Piechocki W.Z. Wei B. Seliger T. Blankenstein R. Kiessling Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
01. Januar 2004 / J Immunol Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells H.J. Kim T. Kammertoens M. Janke O. Schmetzer Z. Qin C. Berek T. Blankenstein
01. Januar 2004 / Gene Ther Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization J. Westermann T. Nguyen-Hoai A. Mollweide G. Richter O. Schmetzer H.J. Kim T. Blankenstein B. Doerken A. Pezzutto
01. August 2004 / Immunity CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions L. Ohl M. Mohaupt N. Czeloth G. Hintzen Z. Kiafard J. Zwirner T. Blankenstein G. Henning R. Foerster
01. Juli 2004 / Eur J Immunol Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors M. Gladow W. Uckert T. Blankenstein
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
01. Januar 2004 / Int J Cancer CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells J.A. Lindencrona S. Preiss T. Kammertoens T. Schueler M. Piechocki W.Z. Wei B. Seliger T. Blankenstein R. Kiessling